2025-521971-29-00招募中3 期
A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 45
- 试验地点
- 26
- 主要终点
- DFS by Investigator assessment
研究概览
简要总结
To compare the efficacy of taletrectinib with that of placebo, as measured by disease-free survival (DFS), in participants with completely resected ROS1-fusion positive (ROS1+) non-small cell lung cancer (NSCLC), regardless of whether they received post-resection adjuvant chemotherapy.
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •1.Histologically confirmed stage IB, II, or IIIA NSCLC (AJCC 9th edition) based on pathological staging
- •Documented ROS1 rearrangement in primary tumor by a validated local assay performed in CLIA-certified or locally equivalent diagnostic laboratories.
- •Adequate tissue is available for prospective central laboratory confirmatory testing. Confirmation of central test positivity is required prior to Randomization. Note: In the event that the local testing assay is the same as the central testing assay, and the local test was conducted in a CLIA-certified laboratory or local equivalent, prospective central confirmation is not needed, but tumor tissue must still be provided for other biomarker studies.
- •Age ≥18 years
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Received definitive locoregional curative surgery for stage IB, II, or IIIA NSCLC. All surgical margins of resection must be negative for tumor.
- •Complete recovery from surgery (including complete wound healing) that was performed ≥4 weeks but no more than 16 weeks before Randomization if no adjuvant chemotherapy was given. Surgery must have occurred ≥4 weeks but no more than 30 weeks prior to Randomization if adjuvant chemotherapy was given. For participants who received post-resection adjuvant chemotherapy, the final dose of chemotherapy must also have occurred at least 7 days before Randomization. All chemotherapy related toxicities must have resolved to baseline or ≤Grade 1 (per CTCAE v5.0) prior to Randomization.
排除标准
- •Has previously received 1 or more of the following cancer treatments: a. Postoperative or planned radiation therapy for the current lung cancer. Note: radiotherapy in the neoadjuvant setting is allowed and must be completed at least 4 weeks prior to Randomization. b. Any adjuvant anticancer therapy (including investigational therapy) for treatment of NSCLC other than standard postoperative platinum-based doublet chemotherapy. Participants should have received no more than 4 cycles of the platinum doublet regimen. Notes: Adjuvant immune checkpoint inhibitor (ICI) treatment is allowed, but participants should have received no more than 4 cycles of the ICI, and at the time of Randomization, have at least 12 weeks of washout from the last dose of the ICI. Any prior immune-related toxicity, such as immune-related hepatitis, colitis, or pneumonitis, must be completely resolved prior to Randomization. c. Neoadjuvant chemotherapy with or without ICIs is allowed. Those treated with prior ICIs are eligible if ≥12 weeks have elapsed after completion of the ICI at the time of Randomization. Any prior immune-related toxicity (if an ICI was given), such as immune-related hepatitis, colitis, or pneumonitis, must be completely resolved prior to Randomization. d. Major surgery (including surgical resection of the primary tumor but excluding placement of vascular access port) within 4 weeks of Randomization. e. Segmentectomies or wedge resections, instead of complete resections, of the primary tumor. Note: These limited resections are allowed for patients with stage IB disease with T2aN0M0, with tumor size >3 to ≤4 cm, and without visceral pleura or central invasion.
- •Use of food or drugs that are known as strong cytochrome P450 (CYP)3A inducers or inhibitors within 14 days prior to Randomization.
- •Any investigational therapy for any condition other than NSCLC within 6 months of Randomization
- •Co-mutations of epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) fusion.
- •History of other malignancies except adequately treated non-melanoma skin cancer, curatively treated in situ cancer, or other tumors curatively treated with no evidence of disease for >3 years after the end of treatment and which, in the opinion of the treating physician, do not have a substantial risk of recurrence of the prior malignancy.
- •Have clinically significant cardiovascular disease within 3 months prior to Randomization
- •Have a known history of uncontrolled hypertension.
- •Experiencing ongoing cardiac dysrhythmias of ≥Grade 2 (CTCAE v5.0), uncontrolled atrial fibrillation of any CTCAE grade, a QT interval corrected by Fridericia's formula (QTcF) of >470 milliseconds, symptomatic bradycardia <45 bpm; undergoing treatment with medication(s) known to be associated with the development of Torsades de Pointes (TdP). Participants with other conditions that, in the opinion of the Investigator, may increase susceptibility to drug-induced TdP are also excluded. Examples include, but are not limited to, congenital long QT syndrome; history of cardiac arrest; family history of sudden cardiac death; or clinically significant structural heart disease such as cardiomyopathy, significant left ventricular hypertrophy, or advanced valvular disease. Clinically significant or persistent hypokalemia, hypomagnesemia, or hypocalcemia must be corrected prior to randomization.
- •Have active and clinically significant bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV); or known human immunodeficiency virus (HIV)- or acquired immunodeficiency syndrome-related illness.
- •Currently have or have a history of interstitial lung disease (ILD), drug-related pneumonitis, or radiation pneumonitis that required steroid treatment.
研究组 & 干预措施
Taletrectinib, Taletrectinib
Test
干预措施: Taletrectinib (Drug)
Placebo matching Taletrectinib capsules
Placebo
干预措施: Placebo matching Taletrectinib capsules (Drug)
结局指标
主要结局
DFS by Investigator assessment
DFS by Investigator assessment
次要结局
- 4 OS rates at 2, 3, 4, and 5 years.
- 1 DFS rates by Investigator assessment at 2, 3, 4, and 5 years.
- 2 Overall survival (OS)
- 3 DFS by blinded independent central review (BICR).
- 5 Central nervous system (CNS) DFS by Investigator assessment and by BICR.
- 6 Plasma concentrations of taletrectinib.
- 7 Adverse events (AEs), as graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0; laboratory abnormalities as graded by CTCAE v5.0; vital signs, physical examinations, and digital electrocardiograms (ECGs).
研究者
Investor Relations
Scientific
Nuvation Bio Inc.
研究点 (26)
Loading locations...
相似试验
招募中
2 期
Taletrectinib in ROS1 Positive Lung Cancer Phase 2 Global StudyNon-small Cell Lung Cancer2024-516604-41-00Anheart Therapeutics Inc.98
招募中
3 期
A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib 100 mg and 50 mg QD in Adult Participants with Nonsegmental Vitiligo2022-502518-98-00Pfizer Inc.355
招募中
3 期
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306)2023-506235-15-00Amgen Inc.145
招募中
3 期
A late stage clinical trial to investigate the efficacy and safety of Osimertinib versus Placebo in patients with stage IA2-IA3 non-small cell lung cancer, following complete tumour resection.2023-509943-28-00AstraZeneca AB21
招募中
3 期
Efficacy and Safety of Selumetinib in Adults with NF1 who have Symptomatic, Inoperable Plexiform Neurofibromas.2023-507336-20-00Astrazeneca AB49